The 3% curcuminoid that outperforms the other 97%

Bisdemethoxycurcumin makes up only ~3% of the curcuminoid complex, yet it's the most potent NF-kB inhibitor of the three curcuminoids. The dominant compound, curcumin itself (~77%), is actually the weakest at nuclear translocation inhibition. The industry standardizes on "95% total curcuminoids", treating three molecules with different mechanisms as one. The company that fractionates and standardizes on bisdemethoxycurcumin specifically could own a new IP category.Publications of interest:https://pmc.ncbi.nlm.nih.gov/articles/PMC8406555/, https://pubmed.ncbi.nlm.nih.gov/17522064/, https://pubmed.ncbi.nlm.nih.gov/18449507/